 |
54 Diseases |  |
75 Trials |
|
75 Trials |  |
6476 News |  |
| «12...1011121314151617181920...7071» |
- || Review, Journal: Infectious Complications of Targeted Therapies in Children with Leukemias and Lymphomas. (Pubmed Central) - Oct 28, 2022
Off-label therapies inotuzumab ozogamicin, brentuximab vedotin, and venetoclax demonstrate low rates of treatment-related grade ≥3 infections, while the addition of bortezomib to standard chemotherapy in T-cell malignancies seems to decrease the infection risk during induction. Prophylaxis, immune reconstitution, and vaccinations for each targeted agent are discussed, along with comparisons to adult studies.
- | Biomarker, Journal: Early Reduction of Glucose Consumption Is a Biomarker of Kinase Inhibitor Efficacy Which Can Be Reversed with GLUT1 Overexpression in Lung Cancer Cells. (Pubmed Central) - Oct 27, 2022
Our results demonstrate that the early inhibition of lung cancer glucose consumption in response to a kinase inhibitor is a strong biomarker of and is often required for the subsequent inhibition of cell growth. Early inhibition of glucose consumption may provide complementary information to other biomarkers in determining whether a drug will effectively limit tumor growth.
- || Xalkori (crizotinib) / Pfizer
PK/PD data, Preclinical, Journal: Predicting fetal exposure of crizotinib during pregnancy: Combining human ex vivo placenta perfusion data with physiologically-based pharmacokinetic modeling. (Pubmed Central) - Oct 26, 2022
In placental tissue, a C of 5.04 mg/L was predicted. In conclusion, PBMP model-based data analysis and the associated p-PBPK modeling approach illustrate how ex vivo placenta perfusion data may be used for fetal exposure predictions.
- | Journal: Cancer Therapy Targeting Fusion Genes in Lung Cancer (Pubmed Central) - Oct 26, 2022
When limited to fusion genes, as of June 2022, crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib are approved for the ALK fusion gene; crizotinib and entrectinib for the ROS1 fusion gene; selpercatinib for the RET fusion gene; entrectinib and larotrectinib for the NTRK fusion gene have been approved in Japan. This article summarizes the therapeutic development of each fusion gene mutation, as well as the therapeutic outcomes and adverse events of the approved drugs.
- Xalkori (crizotinib) / Pfizer
THE IN VITRO EFFECT OF ALK INHIBITORS IN STRN‐ALK ANAPLASTIC THYROID CANCER () - Oct 26, 2022 - Abstract #ATA2022ATA_176;
This article summarizes the therapeutic development of each fusion gene mutation, as well as the therapeutic outcomes and adverse events of the approved drugs. This study permitted to evaluate in vitro the antineoplastic effect of crizotinib in human pATC (with STRN‐ALK), opening the way to future clinical evaluations in these patients.
- | Xalkori (crizotinib) / Pfizer
Journal, IO biomarker: Early Stage Finding of an Immune-Enhanced Genetic Subtype of Nonsmall Cell Lung Cancer Related with T-Cell Depletion. (Pubmed Central) - Oct 25, 2022
C2 were more susceptible to standard chemotherapeutic treatments such paclitaxel, cisplatin, sorafenib, crizotinib, and erlotinib. According to our findings, early-stage NSCLC patients may benefit from receiving treatment with immune checkpoint blockade therapy.
- || Lorbrena (lorlatinib) / Pfizer
Trial completion date, Metastases: A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations (clinicaltrials.gov) - Oct 25, 2022
P1/2, N=334, Active, not recruiting, Sponsor: Pfizer
According to our findings, early-stage NSCLC patients may benefit from receiving treatment with immune checkpoint blockade therapy. Trial completion date: Aug 2022 --> Nov 2022
- | Alunbrig (brigatinib) / Takeda
Trial completion date, Trial termination, Trial primary completion date: Brigatinib Before Brain Irradiation Trial (B3i Trial) (clinicaltrials.gov) - Oct 24, 2022
P2, N=1, Terminated, Sponsor: University of Colorado, Denver
Trial completion date: Aug 2022 --> Nov 2022 Trial completion date: Jul 2025 --> Apr 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2024 --> Apr 2022; Low accrual
- | Journal, HEOR, Real-world evidence: Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer. (Pubmed Central) - Oct 23, 2022
Clinically relevant toxicities occurred across all ALK-TKIs. Treatment modifications due to toxicity may not necessarily compromise outcomes, allowing multiple approaches to deal with ALK-TKI toxicities.
- || Xalkori (crizotinib) / Pfizer
Clinical, Journal: Clinicopathologic Analysis of Inflammatory Myofibroblastic Tumors of the Urinary Bladder. (Pubmed Central) - Oct 22, 2022
There were additionally no recurrences noted after definitive radical or partial cystectomy. These data support organ sparing therapy with aggressive endoscopic management and short-term surveillance in patients with localised IMT, with extirpative surgery reserved for refractory cases.
- | Xalkori (crizotinib) / Pfizer
Journal: ROS1 genomic rearrangements are rare actionable drivers in microsatellite stable colorectal cancer. (Pubmed Central) - Oct 22, 2022
Molecularly targeted treatment with crizotinib induced a rapid and sustained partial response...In summary, the high prevalence of GOPC-ROS1 and noncanonical ROS1 fusions pose diagnostic challenges. We advocate NGS-based comprehensive molecular profiling of MSS CRCs that are wild type for RAS and BRAF and patient enrollment in precision trials.
- | Xalkori (crizotinib) / Pfizer
Journal: Experimental solubility and modeling of Crizotinib (anti-cancer medication) in supercritical carbon dioxide. (Pubmed Central) - Oct 21, 2022
To expand the application of the solubility data, few important solubility models and three cubic equations of sate (cubic EoS) models along with Kwak and Mansoori mixing rules are investigated. Sublimation and salvation enthalpies of Crizotinib dissolution in scCO are calculated.
- | Xalkori (crizotinib) / Pfizer, TGX-221 / Wuhan University, Pfizer, Gilotrif (afatinib) / Boehringer Ingelheim
Journal: Study on the prognosis, immune and drug resistance of m6A-related genes in lung cancer. (Pubmed Central) - Oct 21, 2022
In conclusion, m6A-related genes are important participants in LC and the expression levels of ZC3H13, CBLL1, ELAVL1 and YTHDF1 are significant for prediction and treatment of LC. Researches of drug resistance based on m6A-related genes need to pay more attention for producing new therapeutic strategies of LC and CBLL1 may contribute to target treatment for further research.
- | Xalkori (crizotinib) / Pfizer
Journal: New Indication for Cancer Drug Crizotinib. (Pubmed Central) - Oct 21, 2022
The Food and Drug Administration has approved crizotinib (Xalkori) to treat adult and pediatric patients ages one year and older who have recurrent or refractory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors.The most common adverse effects in adults are vision disorders, nausea, and edema. The most common adverse effects in pediatric patients are vomiting, nausea, diarrhea, abdominal pain, rash, vision disorder, upper respiratory tract infection, cough, pyrexia, musculoskeletal pain, fatigue, edema, constipation, and headache.
- | Xalkori (crizotinib) / Pfizer
Observational data, Retrospective data, Journal, Real-world evidence: Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study). (Pubmed Central) - Oct 21, 2022
P=N/A
The observed incidence of ALK translocations in NSCLC patients is aligned with published reports. This analysis of the real-world clinical experience in Spain confirms the therapeutic benefit and safety of crizotinib in advanced/metastatic ALK-positive NSCLC.
- | Xalkori (crizotinib) / Pfizer
Journal: The therapeutic inhibition of topoisomerase inhibitor and crizotinib combination in EGFR wild and mutant lung cancer cells. (Pubmed Central) - Oct 21, 2022
Moreover, the synergistic mechanism of the combination was consistent with the in vitro cell experiment by regulating EGFR signaling pathways. Collectively, we proposed a preclinical rationale and potential formulation for the use of a combination therapy consisting of the topoisomerase inhibitor TPT and the ALK-TKI CRI for treatment of lung cancers.
- | Xalkori (crizotinib) / Pfizer
Journal: Construction of crizotinib resistant models with CD74-ROS1 D2033N and CD74-ROS1 S1986F point mutations to explore resistance mechanism and treatment strategy. (Pubmed Central) - Oct 21, 2022
The results showed that the combination could significantly inhibit the proliferation, invasion and migration of mutant cells. In conclusion, we proved that CD74-ROS1 D2033N and CD74-ROS1 S1986F point mutant NSCLC cells were resistant to crizotinib through the activation of FAK/PI3K/AKT signaling pathway, and inhibiting FAK/PI3K/AKT signaling pathway activation by defactinib could overcome drug resistance in mutant cells.
- |||| Xalkori (crizotinib) / Pfizer
Clinical: Case report @ClinicalLung showing a novel PRKAR1A:MET fusion in NSCLC with a dramatic response to crizotinib. #MET fusions are rare with multiple different fusion partners described and they may not all be equally actionable. More work needed here. https://t.co/WpZM1Cp17h (Twitter) - Oct 21, 2022
- || I am forever confusing venetoclax and navitoclax. And cabozantinib and crizotinib. (Twitter) - Oct 19, 2022
- Xalkori (crizotinib) / Pfizer, Tagrisso (osimertinib) / AstraZeneca
PROGNOSTIC FACTOR OF ROS1 REARRANGEMENTS CONCOMITANCE IN PATIENTS WITH EGFR-MUTATED LUNG ADENOCARCINOMA () - Oct 19, 2022 - Abstract #AIOM2022AIOM_19;
Although not statistically significant, our observations suggest that concomitant alteration of ROS1 might worse patients’ outcome and decrease EGFR-TKIs efficacy. The increase of sample size, longer follow-up and prospective studies, could help to achieve statistical significance in the future.
- Xalkori (crizotinib) / Pfizer
CRIZOTINIB IN ANAPLASTIC LYMPHOMA KINASE (ALK) REARRANGED NON-SMALLCELL LUNG CANCER (NSCLC): REAL WORLD DATA FROM THE ITALIAN SPECIALK TRIAL () - Oct 19, 2022 - Abstract #AIOM2022AIOM_17;
The increase of sample size, longer follow-up and prospective studies, could help to achieve statistical significance in the future. Real world data confirm that crizotinib is an effective and well tolerated agent in ALK+ NSCLC, supporting its usage when second or third generation ALK inhibitors are not available or contraindicated.
- Xalkori (crizotinib) / Pfizer
CRIZOTINIB IN ROS1+ NSCLC: LONG-TERM OUTCOME OF PATIENTS WITH BRAIN METASTASES INCLUDED IN THE PHASE II METROS TRIAL () - Oct 19, 2022 - Abstract #AIOM2022AIOM_14;
At a median follow-up >4 years, crizotinib confirmed its marked activity in ROS1+ NSCLC. Patients with BMs had higher risk of disease progression and death, highlighting the need for brain-penetrant drugs in the management of the disease.
- EFFICACY, SAFETY AND BRAIN METASTASES CONTROL OF FIRST-LINE TREATMENT STRATEGIES FOR ANAPLASTIC LYMPHOMA KINASE-POSITIVE NON-SMALL CELL LUNG CANCER: A NETWORK META-ANALYSIS (Tiziano Room 1) - Oct 19, 2022 - Abstract #AIOM2022AIOM_8;
Patients received eight different treatments: alectinib (300 mg and 600 mg), brigatinib, ceritinib, crizotinib, ensartinib, lorlatinib, and chemotherapy. In our network meta-analysis, alectinib and lorlatinib resulted the therapeutics with the highest probability to be the best first-line options for ALK-rearranged NSCLC patients ensuring prolonged disease control.
- Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
CABINMET: CABOZANTINIB IN MET DEREGULATED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (Tiziano Room 1) - Oct 19, 2022 - Abstract #AIOM2022AIOM_6;
Cabozantinib has lack of efficacy in MET mutant NSCLC. MET amplified cohort is still recruiting
- Lorbrena (lorlatinib) / Pfizer
IMPACT OF TP53 MUTATIONS IN ROS1 POSITIVE NSCLC RECEIVING LORLATINIB: FINAL RESULTS OF THE PFROST TRIAL (Tiziano Room 1) - Oct 19, 2022 - Abstract #AIOM2022AIOM_5;
Introduction: Lorlatinib demonstrated activity in crizotinib-refractory ROS1+ NSCLC, especially in absence of acquired ROS1 mutations. In the PFROST study, presence of TP53 mutations identified a subset of ROS1+ individuals at high risk of progression and death for which more potent and aggressive strategies are needed.
- || Review, Journal: ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences. (Pubmed Central) - Oct 19, 2022
Across these counties, next-generation TKIs are preferred for patients with progressing BM lesions. Although next-generation ALK TKIs demonstrate significant activity in these patients and following progression on crizotinib, access remains a challenge for personalized therapy.
- || Xalkori (crizotinib) / Pfizer
P2 data, Journal, HEOR: Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC. (Pubmed Central) - Oct 18, 2022
P2
This is the largest trial of an ALK/ROS1 inhibitor to treat patients with ROS1-positive advanced NSCLC and provides a new benchmark for OS in East Asian patients. The QoL and safety profile with long-term follow-up were consistent with previous reports and support the continued use of crizotinib in the treatment of patients with ROS1-positive advanced NSCLC.
- | Journal: Explainable artificial intelligence for precision medicine in acute myeloid leukemia. (Pubmed Central) - Oct 18, 2022
We successfully validated the results in three different large-scale screening experiments. We believe that XAI will help healthcare providers and drug regulators better understand AI medical decisions.
- | Xalkori (crizotinib) / Pfizer, Bay11-7082 / InvivoGen
Journal: Multiple approaches to repurposing drugs for neuroblastoma. (Pubmed Central) - Oct 18, 2022
We demonstrated that pyronaridine (SH-SY5Y IC 1.70 µM, SK-N-AS IC 3.45 µM), BAY 11-7082 (SH-SY5Y IC 0.85 µM, SK-N-AS IC 1.23 µM), niclosamide (SH-SY5Y IC 0.87 µM, SK-N-AS IC 2.33 µM) and fingolimod (SH-SY5Y IC 4.71 µM, SK-N-AS IC 6.11 µM) showed cytotoxicity against NB...Pyronaridine was also tested in combinations in SH-SY5Y cells and demonstrated an antagonistic effect with either etoposide or crizotinib...We have also described several analogs of pyronaridine to explore the structure-activity relationship against cell lines. We describe multiple molecules demonstrating cytotoxicity against NB and the further evaluation of these molecules and combinations using other NB cells lines and in vivo models will be important in the future to assess translational potential.
- || Xalkori (crizotinib) / Pfizer
Review, Journal: The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives. (Pubmed Central) - Oct 15, 2022
Following the promising results of Crizotinib, a first-generation ALK inhibitor (ALK-i), other second-generation and more recently third-generation TKIs have been developed and are currently a landmark in NSCLC treatment, leading to a significant improvement in patients prognosis...This review aims to provide an overview of underlying molecular alterations of ALK-i resistance and point out promising role of liquid biopsy in predicting tumor response and monitoring resistance mutations. The purpose of this review is also to summarize current approval for ALK-rearranged NSCLC patients, to help clinicians in making decisions on therapeutic sequence, and to deepen the role of clinicopathological and genomic characteristics influencing patients' prognosis during treatment with ALK-i.
- | Xalkori (crizotinib) / Pfizer
Journal: Photocatalytic Activity of TiO for the Degradation of Anticancer Drugs. (Pubmed Central) - Oct 15, 2022
The formation of seven degradation products for imatinib and fifteen for crizotinib during the optimal photocatalytic process was monitored by high-resolution mass spectrometry (HPLC-QqTOF). Since the newly formed products may pose a hazard to the environment, their toxicity was studied using Vibrio fischeri, where the significant luminescence inhibition was assessed for the mixture of crizotinib degradants during the photocatalysis from 90 to 120 min.
- Xalkori (crizotinib) / Pfizer
Successful crizotinib retreatment after crizotinib-related interstitial lung disease in a patients with ROS1-rearranged advanced lung adenocarcinoma () - Oct 15, 2022 - Abstract #APSR2022APSR_402;
- | Xalkori (crizotinib) / Pfizer
Journal: Curable Response to Crizotinib in a Patient with Liver Metastatic Inflammatory Myofibroblastic Tumor Carrying a TFG-ROS1 Fusion. (Pubmed Central) - Oct 14, 2022
Since the newly formed products may pose a hazard to the environment, their toxicity was studied using Vibrio fischeri, where the significant luminescence inhibition was assessed for the mixture of crizotinib degradants during the photocatalysis from 90 to 120 min. No abstract available
- | Journal, HEOR: Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China. (Pubmed Central) - Oct 11, 2022
For Chinese patients with advanced ALK-positive NSCLC, ensartinib was a cost-effective option compared with crizotinib, and was a dominant alternative to ceritinib and brigatinib. Although lorlatinib and alectinib were associated with prolonged survival compared with ensartinib, they were less cost-effective than ensartinib due to the overwhelming total costs.
- foritinib (SAF-189) / Fosun Pharma
A phase II study of SAF-189s in patients with advanced ROS1 fusion-positive non-small cell lung cancer (Exhibition / Poster Area) - Oct 9, 2022 - Abstract #ESMOAsia2022ESMO_Asia_885;
P1/2
Conclusions These findings demonstrate the promising clinical activity and a tolerable toxicity profile of SAF-189s in pts with advanced ROS1+ NSCLC, with or without crizotinib treatment. Clinical trial identification NCT04237805.
- Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis, Alecensa (alectinib) / Roche
Real-world data on treatment outcome of ALK positive non-small cell lung cancer from an Indian multi-centric cancer registry (Exhibition / Poster Area) - Oct 9, 2022 - Abstract #ESMOAsia2022ESMO_Asia_875;
Patients who received ALKi in second or later lines fared much better in comparison to chemotherapy. Use of ALKi in any lines of therapy resulted in significantly prolonged OS.
- | Journal, Epigenetic controller: Assessment of alterations in histone modification function and guidance for death risk prediction in cervical cancer patients. (Pubmed Central) - Oct 7, 2022
Patients with high HMAG scores were more suitable for the treatment of CHIR-99021, embelin, FTI-277, JNK-9L, JQ12, midostaurin, PF-562271, pyrimethamine, and thapsigargin, and patients with low HMAG scores were more suitable for the treatment of BMS-536924, CP466722, crizotinib, PHA-665752, rapamycin, and TAE684. We comprehensively evaluated the histone modification status in cervical cancer patients and revealed histone modification-associated prognostic genes to construct the HMAG signature, aiming to provide a new insight into prognosis prediction and precise clinical treatment.
- | Lorbrena (lorlatinib) / Pfizer
Preclinical, Journal: Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism. (Pubmed Central) - Oct 4, 2022
This study demonstrated that the combination of p53 protein agonist and lorlatinib may provide a new therapeutic strategy for NSCLC patients with lorlatinib resistance and TP53 mutation. Furthermore, the results also provide guidance for selecting optimal chemo-regimens for NSCLC patients after ALK-TKIs failure.
- ||| Xalkori (crizotinib) / Pfizer, Lumakras (sotorasib) / Amgen
We do not know, but I suspect it is related to overlapping tox with particular TKIs. Pneumonitis with osi, LFTs with crizotinib or sotorasib. VEGF TKIs with no red flags in other cancers or NSCLC (Twitter) - Oct 3, 2022
- | Journal: Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline. (Pubmed Central) - Oct 1, 2022
For patients with a RET rearrangement, a PS of 0-2, and previously untreated NSCLC, clinicians may offer selpercatinib or pralsetinib. In second line, for patients with a RET rearrangement who have not received RET-targeted therapy, clinicians may offer selpercatinib or pralsetinib.Additional information is available at www.asco.org/thoracic-cancer-guidelines.
- | Mekinist (trametinib) / Novartis, Tagrisso (osimertinib) / AstraZeneca
Journal: Response to osimertinib plus trametinib in a heavily treated epidermal growth factor receptor (EGFR)-positive NSCLC harboring a rare, acquired rapidly accelerated fibrosarcoma B-type (BRAF) p.D594N mutation: a case report. (Pubmed Central) - Oct 1, 2022
To the best of our knowledge, our case is the first to provide clinical evidence that trametinib plus osimertinib was effective for EGFR-mutant NSCLC patients with acquired BRAF p.D594N mutation. More supporting data and systematic validation studies are needed for comprehensive understanding of this therapy strategy and future applications.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Doxorubicin-Induced TrkAIII Activation: A Selection Mechanism for Resistant Dormant Neuroblastoma Cells. (Pubmed Central) - Oct 1, 2022
The inhibitory effects of lestaurtinib, entrectinib, crizotinib, and LY294002 on the Dox-induced TrkAIII and Akt phosphorylation and resistance confirm roles for TrkAIII and IP3-K consistent with Dox-induced, TrkAIII-mediated pro-survival IP3K/Akt signaling. This mechanism has the potential to select resistant dormant TrkAIII-expressing NB cells, supporting the use of Trk inhibitors during Dox therapy in TrkAIII-expressing NBs.
- || Review, Journal, PD(L)-1 Biomarker, IO biomarker: Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies. (Pubmed Central) - Oct 1, 2022
Some of the mechanisms of resistance include downregulation of the target, antigen escape, increased PD-L1 expression and T-cell exhaustion, mutations altering the signaling pathway, and agent binding site mutations. In this manuscript, we discuss and highlight the mechanism of action of the above listed agents as well as the different mechanisms of resistance to these agents as seen in lymphoproliferative disorders.
- Alecensa (alectinib) / Roche
Durable complete response to Alectinib in a second line setting in metastatic ALK+ve NSCLC patient with poor PS with initial NG tube administration (Summit 2) - Oct 1, 2022 - Abstract #ESMOAsia2022ESMO_Asia_395;
On follow up in March 2022, PET CT and MRI brain confirmed ongoing complete response at more than 3 years of follow up with patient doing well and carrying out activities of daily living independently. No significant toxicity nor dose delay were noted.
- Xalkori (crizotinib) / Pfizer, envonalkib (TQ-B3139) / Sino Biopharm
Envonalkib vs crizotinib in treatment-naïve advanced ALK-positive NSCLC: A randomized, multicenter, phase III trial (Hall 406) - Oct 1, 2022 - Abstract #ESMOAsia2022ESMO_Asia_288;
P3
Conclusions Compared with Cri, Env significantly prolonged PFS in advanced ALK-positive NSCLC pts who had not received a prior ALK inhibitor, and showed greater advantages in controlling BMs. The safety profiles following Env treatment were manageable.
- Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
Alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve advanced ALK+ non-small cell lung cancer (NSCLC): 5-year update from the phase III ALESIA study (Hall 406) - Oct 1, 2022 - Abstract #ESMOAsia2022ESMO_Asia_280;
P3
ALC had a favourable safety profile vs CRZ despite longer treatment duration (42.3 vs 12.6 m), with fewer Grade 3–5 AEs (48 vs 55%), serious AEs (28 vs 29%) or AEs leading to treatment discontinuation (11 vs 15%). Conclusions With ≥5 years follow-up, 1L alectinib 600mg BID continues to provide clinical benefit to Asian pts with advanced ALK+ NSCLC, with no new safety concerns.
- Xalkori (crizotinib) / Pfizer, Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
ALTA-3: A randomized trial of brigatinib (BRG) vs alectinib (ALC) in crizotinib (CRZ)-refractory advanced ALK+ NSCLC (Hall 406) - Oct 1, 2022 - Abstract #ESMOAsia2022ESMO_Asia_277;
P3
Conclusions At the IA, BIRC PFS was numerically similar between arms. No new safety findings were observed, with safety profiles consistent with known BRG and ALC profiles.
- | Xalkori (crizotinib) / Pfizer, Avastin (bevacizumab) / Roche
Journal, PD(L)-1 Biomarker, IO biomarker: Optimal Treatments for NSCLC Patients Harboring Primary or Acquired MET Amplification. (Pubmed Central) - Sep 30, 2022
MET-TKIs might be an optional treatment with worth-expecting efficacy. However, chemotherapy plus bevacizumab could benefit the subpopulation of patients harboring acquired MET amplification after the failure of EGFR-TKIs.
- | Xalkori (crizotinib) / Pfizer, Tabrecta (capmatinib) / Incyte, Novartis, Tepmetko (tepotinib) / EMD Serono
Journal: Management of Peripheral Edema in Patients with MET Exon 14-Mutated Non-small Cell Lung Cancer Treated with Small Molecule MET Inhibitors. (Pubmed Central) - Sep 29, 2022
Although not usually required, discontinuation of MET inhibitor treatment generally resolves peripheral edema. Early diagnosis and management, as well as patient information and education, are vital to decrease the clinical burden associated with edema, and to reinforce capmatinib treatment adherence.
- | Journal: Investigation of cell signalings and therapeutic targets in PTPRK-RSPO3 fusion-positive colorectal cancer. (Pubmed Central) - Sep 29, 2022
Among these pathways, the most altered cancer genes (ALK, ACSL3, AXIN, MYC, TP53, GNAQ, ACVR2A, and FAS) specific for P:R fusion and involved in multiple cancer pathways were considered to have a key role in P:R fusion-positive CRC. Based on the drug-target network analysis, crizotinib, alectinib, lorlatinib, brigatinib, ceritinib, erdafitinib, infigratinib and pemigatinib were selected as putative therapeutic candidates, since they were already used in routine clinical practice in other cancer types and target genes of the drugs were involved in multiple cancer-pathways.